Enzymotec boosts production capacity
Enzymotec’s line includes: SharpPS line, a lecithin-derived cognitive enhancer, InFat, a structured lipid that significantly improves calcium absorption and energy intake of newborns.
30/05/05 Enzymotec has increased its production capacity due to the success of its innovative product line for dietary supplements and functional foods.
"The company made significant investments in expanding its Israeli site, in order to meet our customers’ needs for an efficient supply on time and by thus strengthening our key market position”, says Dr. Ariel Katz, CEO of Enzymotec. “We decided to increase the production capacity in order to answer the expected increasing in the demand from both dietary supplements and functional food producers in several categories, so we were obliged to endure the high demand within a few months period.”
Enzymotec’s line includes: SharpPS line, a lecithin-derived cognitive enhancer, InFat, a structured lipid that significantly improves calcium absorption and energy intake of newborns: CardiaBea, an innovative nutrient that can simultaneously reduce all CVD risk factors including: “bad” cholesterol (LDL), triglycerides and oxidative stress.
www.enzymotec.com
